Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Schizophrenia News

A brain puzzle against an orange background
News
Most Patients With Schizophrenia Relapse-Free With Paliperidone Palmitate, Open Label Extension Study Finds
08/01/2024
In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years.
In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years.
In a 2-year open-label extension...
08/01/2024
Psych Congress Network
News
Some Antipsychotics Linked To Elevated Pneumonia Risk
07/17/2024
Pneumonia in patients with schizophrenia is associated with the use of specific antipsychotics, according to study findings published in JAMA Psychiatry.
Pneumonia in patients with schizophrenia is associated with the use of specific antipsychotics, according to study findings published in JAMA Psychiatry.
Pneumonia in patients with...
07/17/2024
Psych Congress Network
a doctor writes notes
News
Subcutaneous Olanzapine Long-Acting Injection Meets Efficacy Endpoint in Phase 3 Trial
06/25/2024
An investigational, once-monthly, subcutaneous long-acting injection of olanzapine called TEV-‘749 met its primary endpoint in the efficacy portion of the phase 3 SOLARIS trial.
An investigational, once-monthly, subcutaneous long-acting injection of olanzapine called TEV-‘749 met its primary endpoint in the efficacy portion of the phase 3 SOLARIS trial.
An investigational,...
06/25/2024
Psych Congress Network

Advertisement

A doctor takes notes on paper on a clipboard sitting on a desk
News
Third Xanomeline-Trospium Trial Shows Improvement in Schizophrenia Symptoms
06/18/2024
Jolynn Tumolo
Xanomeline-trospium chloride was efficacious and well-tolerated in adults with schizophrenia experiencing acute psychosis, according to trial results published in JAMA Psychiatry. “In the phase 3 EMERGENT-3 trial in people with...
Xanomeline-trospium chloride was efficacious and well-tolerated in adults with schizophrenia experiencing acute psychosis, according to trial results published in JAMA Psychiatry. “In the phase 3 EMERGENT-3 trial in people with...
Xanomeline-trospium chloride was...
06/18/2024
Psych Congress Network
A patient holds a couple of small pills in one hand and a glass of water in the other
News
Add-on Evenamide Improves Symptoms in Patients With Schizophrenia
05/21/2024
Jolynn Tumolo
In patients with an inadequate response to a second-generation antipsychotic, adding evenamide improved symptoms, the drug’s developer Newron Pharmaceuticals recently announced.
In patients with an inadequate response to a second-generation antipsychotic, adding evenamide improved symptoms, the drug’s developer Newron Pharmaceuticals recently announced.
In patients with an inadequate...
05/21/2024
Psych Congress Network
two animated heads in profile
News
Blonanserin May Improve Social Functioning for Individuals With First-Episode Schizophrenia
04/05/2024
Brionna Mendoza
Blonanserin, a novel atypical antipsychotic marketed under the brand name Lonasen, has demonstrated efficacy for improving social functioning in individuals with first-episode schizophrenia.
Blonanserin, a novel atypical antipsychotic marketed under the brand name Lonasen, has demonstrated efficacy for improving social functioning in individuals with first-episode schizophrenia.
Blonanserin, a novel atypical...
04/05/2024
Psych Congress Network

Advertisement

A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
News
Changes in Same Brain Cells May Underlie Cognitive Impairment in Both Schizophrenia and Aging
03/08/2024
Brionna Mendoza
An Ivy League research team has proposed that a similar collection of changes in brain tissue gene activity may underlie the cognitive impairment that often accompanies schizophrenia and aging.
An Ivy League research team has proposed that a similar collection of changes in brain tissue gene activity may underlie the cognitive impairment that often accompanies schizophrenia and aging.
An Ivy League research team has...
03/08/2024
Psych Congress Network
A man sits on the couch holding his cat
News
Cat Ownership Linked With Increased Risk for Schizophrenia and Related Disorders
02/07/2024
Brionna Mendoza
Cat ownership before the age of 25 is associated with a two-fold greater risk of developing schizophrenia-related disorders, according to results from a systematic review and meta-analysis published in Schizophrenia Bulletin.
Cat ownership before the age of 25 is associated with a two-fold greater risk of developing schizophrenia-related disorders, according to results from a systematic review and meta-analysis published in Schizophrenia Bulletin.
Cat ownership before the age of...
02/07/2024
Psych Congress Network
two profiles of people in illustrated style
News
Once-Weekly Oral Risperidone Comparable to Daily Risperdal for Schizophrenia
01/16/2024
Brionna Mendoza
Oral risperidone (LYN-005) administered once a week shares a comparable pharmacokinetic profile with immediate-release oral Risperdal taken daily in adult patients living with schizophrenia.
Oral risperidone (LYN-005) administered once a week shares a comparable pharmacokinetic profile with immediate-release oral Risperdal taken daily in adult patients living with schizophrenia.
Oral risperidone (LYN-005)...
01/16/2024
Psych Congress Network

Advertisement

a doctor and patient sit on couches talking
News
aLAIs a Useful Treatment Option for Schizophrenia, Study Results Underscore
01/05/2024
Brionna Mendoza
Atypical long-acting injectable (aLAI) antipsychotic medications are useful for the treatment of schizophrenia, especially in patients who experienced persistent psychotic symptoms and had trouble maintaining consistent adherence.
Atypical long-acting injectable (aLAI) antipsychotic medications are useful for the treatment of schizophrenia, especially in patients who experienced persistent psychotic symptoms and had trouble maintaining consistent adherence.
Atypical long-acting injectable...
01/05/2024
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use